PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19681813-1	2009	Tacrolimus, a cornerstone immunosuppressant, is widely available as a twice-daily formulation (Tacrolimus BID).	Tacrolimus	0-10	BH3 interacting domain death agonist	Homo sapiens	106-109	
19681813-1	2009	Tacrolimus, a cornerstone immunosuppressant, is widely available as a twice-daily formulation (Tacrolimus BID).	Tacrolimus	95-105	BH3 interacting domain death agonist	Homo sapiens	106-109	
19681813-3	2009	This study compared the pharmacokinetics (PK) of tacrolimus in de novo kidney transplant patients treated with Tacrolimus QD or Tacrolimus BID.	Tacrolimus	49-59	BH3 interacting domain death agonist	Homo sapiens	139-142	
19681813-9	2009	Mean AUC(0-24) of tacrolimus on day 1 was approximately 30% lower for Tacrolimus QD than Tacrolimus BID (232 and 361 ng.h/mL, respectively), but was comparable by day 4.	Tacrolimus	18-28	BH3 interacting domain death agonist	Homo sapiens	100-103	
19681813-12	2009	Tacrolimus QD can be administered once daily in the morning on the basis of the same systemic exposure and therapeutic drug monitoring concept as Tacrolimus BID.	Tacrolimus	0-10	BH3 interacting domain death agonist	Homo sapiens	157-160